Johnson & Johnson Innovation Opens JLABS @ NYC
06/25/2018
JLABS @ NYC can accommodate up to 30 biotech, pharmaceutical, medical device, consumer and health tech companies and opens with 26 resident companies, including the four winners of the JLABS @ NYC QuickFire Challenge.
"Johnson & Johnson has deep entrepreneurial roots in New York and we are pleased to see our unique JLABS model applied in this rich ecosystem to foster the creation of new healthcare innovations that have the potential to change the trajectory of health for humanity," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "Expanding our JLABS network to NYC will link entrepreneurs around the region with Johnson & Johnson Innovation experts, allowing some of the brightest minds in healthcare to work collaboratively in a shared space."
"This new 21st century incubator supports our efforts to boost economic growth by investing in cutting-edge research and technologies that advance human health," Governor Cuomo said. "By investing in JLABS @ NYC, we're connecting early-stage companies with the tools, resources, and networks to succeed while enhancing the life sciences industry and fostering job growth across New York."
"For too long, patients and consumers have not fully benefited from the incredible genius throughout the world. NYC and its environs are home to some of the greatest minds in scientific innovation, whose skills and their spirit have so much to offer," said Melinda Richter, Global Head of JLABS at Johnson & Johnson Innovation. "JLABS provides those innovators the environment they need to deliver life-enhancing, life-saving solutions to the people who need them. By opening up vital industry connections, entrepreneurial programs and a capital-efficient, flexible platform to help alleviate the cost burden that typically slows or kills innovation, we know NYC will light up our world."
"The New York Genome Center is honored to partner with Johnson & Johnson Innovation and New York State to bring the JLABS network to New York, further strengthening the life sciences sector," said Cheryl A. Moore, NYGC President & COO. "NYGC works to translate genomic research into new diagnostic tools and treatments for human disease, which is in perfect harmony with JLABS' vision of providing a platform to support emerging companies in transforming scientific discoveries into breakthrough healthcare products. We are excited to see the future developments from JLABS @ NYC and we appreciate the Governor's leadership and support in advancing life sciences infrastructure in New York."
JLABS facilities have incubated more than 370 companies to date, advancing biotech, pharmaceutical, medical device, consumer and health tech programs. JLABS @ NYC will follow the same no-strings-attached approach across all JLABS locations: San Diego; San Francisco; South San Francisco; Boston; Lowell, MA; Houston; Toronto; Beerse, Belgium; and Shanghai.
Project Announcements
Kikkoman Foods Plans Jefferson, Wisconsin, Operations
04/26/2024
BWX Technologies Expands Cambridge, Ontario, Nuclear Production Operations
04/26/2024
Greenheck Group Plans Knoxville, Tennessee, Operations
04/26/2024
Local Bounti Plans Pasco, Washington, Indoor Agricultural Operations
04/26/2024
Innovative Construction Group Plans Siler City, North Carolina, Production Operations
04/26/2024
Crystal Window and Door Systems Plans Mansfield, Texas, Headquarters-Production Operations
04/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
Making Hybrid More Human in 2024
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024